- Home
- ABUS vs MGTX Comparison
ABUS vs MGTX Comparison
Compare ABUS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABUS | MGTX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.7M | 610.1M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ABUS | MGTX |
|---|---|---|
| Price | $4.26 | $7.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $23.83 |
| AVG Volume (30 Days) | ★ 2.3M | 300.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,171,000.00 | ★ $33,279,000.00 |
| Revenue This Year | $125.30 | N/A |
| Revenue Next Year | N/A | $569.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 137.42 |
| 52 Week Low | $2.71 | $4.73 |
| 52 Week High | $5.10 | $9.73 |
Technical Indicators
Market Signals| Indicator | ABUS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 46.35 |
| Support Level | $4.23 | $7.23 |
| Resistance Level | $4.69 | $7.50 |
| Average True Range (ATR) | 0.23 | 0.38 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 6.25 | 55.97 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.